Abbott Laboratories May Soon Launch a Game-Changing New Device in the U.S.
Abbott Laboratories' business has underwhelmed investors in 2023, as testing numbers are down big. Growth in its medical devices was the only bright spot in the company's recent earnings report.
The Value Deepens for Medtech Stocks: Reversal Imminent
Results from Johnson & Johnson NYSE: JNJ and Abbott Laboratories NYSE: ABT foreshadow good news for MedTech investors. Both companies outperformed on the top and bottom lines, driven by broad stren...
7 Blue-Chip Stocks to Buy on the Dip
While there are many ways to position yourself in the market during this ambiguous juncture, one of the most straightforward approaches involves targeting blue-chip stocks to buy on the dip. By def...
Abbott Earnings Show Obesity Drug Worries Are Overblown
CEO Robert Ford said more users of its glucose monitoring system were using the device while also taking new obesity drugs.
'We don't see' weight-loss drugs impacting medical devices' sales, says Abbott CEO Robert Ford
Robert Ford, Abbott chairman and CEO, joins 'Closing Bell Overtime' to talk Q3 earnings, the impact of weight loss drugs on their product and more.
Abbott (ABT) Q3 Earnings and Revenues Surpass, Margins Dip
Abbott (ABT) reports solid underlying base business performance in the third quarter of 2023.
Abbott Laboratories 3Q earnings top estimates on strong medical devices sales growth
Abbott Laboratories (NYSE:ABT) shares rose after the healthcare technology company posted a third quarter earnings beat and provided strong full-year guidance. While revenue decreased 2.8% year-ove...
Abbott (ABT) Beats Q3 Earnings and Revenue Estimates
Abbott (ABT) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.10 per share. This compares to earnings of $1.15 per share a year ago.
Oversold and Overextended, Abbott Laboratories is a Great Buy
Abbott Laboratories NYSE: ABT share price has trended lower for nearly 2 years, but that trend is over. The impact of COVID on sales and the post-COVID letdown were cause enough for the market to s...
Abbott Raises Outlook, Boosted By 'Whopping' Growth Of Diabetes Device
Abbott stock rose moderately Wednesday after the company beat third-quarter expectations and raised the midpoint of its earnings view.
Abbott Stock Is Rising. Earnings Beat and Guidance Was Strong.
Healthcare-products firm Abbott beat third-quarter estimates despite a drop in sales of Covid-19 testing kits. It raised the midpoint of earnings guidance for the year.
Abbott beats profit estimates on strong sales of devices, diagnostics
Abbott Laboratories on Wednesday tightened its profit forecast for the year after beating estimates for third-quarter earnings due to strong demand for its medical devices and diagnostics products.
Should You Buy Abbott (ABT) Ahead of Earnings?
Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Which Is A Better Pick – Abbott Stock Or Amgen?
There is more to the comparison, and in the sections below, we discuss why we believe ABT will offer better returns than AMGN in the next three years.
Related Companies